These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 31923345)
1. A novel molecular link between HOXA9 and WNT6 in glioblastoma identifies a subgroup of patients with particular poor prognosis. Gonçalves CS; Xavier-Magalhães A; Martins EP; Pinto AA; Pires MM; Pinheiro C; Reis RM; Sousa N; Costa BM Mol Oncol; 2020 Jun; 14(6):1224-1241. PubMed ID: 31923345 [TBL] [Abstract][Full Text] [Related]
2. Gonçalves CS; Vieira de Castro J; Pojo M; Martins EP; Queirós S; Chautard E; Taipa R; Pires MM; Pinto AA; Pardal F; Custódia C; Faria CC; Clara C; Reis RM; Sousa N; Costa BM Theranostics; 2018; 8(17):4805-4823. PubMed ID: 30279739 [TBL] [Abstract][Full Text] [Related]
3. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients. Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941 [TBL] [Abstract][Full Text] [Related]
4. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
5. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009 [TBL] [Abstract][Full Text] [Related]
6. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Costa BM; Smith JS; Chen Y; Chen J; Phillips HS; Aldape KD; Zardo G; Nigro J; James CD; Fridlyand J; Reis RM; Costello JF Cancer Res; 2010 Jan; 70(2):453-62. PubMed ID: 20068170 [TBL] [Abstract][Full Text] [Related]
7. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker. Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653 [TBL] [Abstract][Full Text] [Related]
8. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624 [TBL] [Abstract][Full Text] [Related]
9. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas. Paul Y; Mondal B; Patil V; Somasundaram K Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842 [TBL] [Abstract][Full Text] [Related]
10. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion. Chen SC; Lo CM; Wang SH; Su EC BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275 [TBL] [Abstract][Full Text] [Related]
11. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway. Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987 [TBL] [Abstract][Full Text] [Related]
12. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas. Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038 [TBL] [Abstract][Full Text] [Related]
13. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling. Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959 [TBL] [Abstract][Full Text] [Related]
14. Cadherin-3 is a novel oncogenic biomarker with prognostic value in glioblastoma. Martins EP; Gonçalves CS; Pojo M; Carvalho R; Ribeiro AS; Miranda-Gonçalves V; Taipa R; Pardal F; Pinto AA; Custódia C; Faria CC; Baltazar F; Sousa N; Paredes J; Costa BM Mol Oncol; 2022 Jul; 16(14):2611-2631. PubMed ID: 34919784 [TBL] [Abstract][Full Text] [Related]
15. The long non-coding RNA Xavier-Magalhães A; Gonçalves CS; Fogli A; Lourenço T; Pojo M; Pereira B; Rocha M; Lopes MC; Crespo I; Rebelo O; Tão H; Lima J; Moreira R; Pinto AA; Jones C; Reis RM; Costello JF; Arnaud P; Sousa N; Costa BM Oncotarget; 2018 Mar; 9(21):15740-15756. PubMed ID: 29644006 [TBL] [Abstract][Full Text] [Related]
16. Wnt-Induced Stabilization of KDM4C Is Required for Wnt/β-Catenin Target Gene Expression and Glioblastoma Tumorigenesis. Chen Y; Fang R; Yue C; Chang G; Li P; Guo Q; Wang J; Zhou A; Zhang S; Fuller GN; Shi X; Huang S Cancer Res; 2020 Mar; 80(5):1049-1063. PubMed ID: 31888886 [TBL] [Abstract][Full Text] [Related]
17. Association between glioblastoma cell-derived vessels and poor prognosis of the patients. Mei X; Chen YS; Zhang QP; Chen FR; Xi SY; Long YK; Zhang J; Cai HP; Ke C; Wang J; Chen ZP Cancer Commun (Lond); 2020 May; 40(5):211-221. PubMed ID: 32359215 [TBL] [Abstract][Full Text] [Related]
18. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668 [TBL] [Abstract][Full Text] [Related]
19. DNA Methylation Analysis Identifies Patterns in Progressive Glioma Grades to Predict Patient Survival. Weng JY; Salazar N Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498463 [TBL] [Abstract][Full Text] [Related]
20. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]